United States: Commission-Based Sales Agreements For Medical Supplies And Equipment: More Whistleblower Activity On The Horizon?

A Wide Range of Industries Should Evaluate Their Compensation Practices to Help

Jerome Hoffman is a Partner in the Tallahassee office and Keith Koford is Senior Counsel in the Miami office.


  • The common industry practice of compensating independent contractor sales representatives on a "percentage of sales" commission basis may be creating an enhanced risk of False Claims Act liability for illegal kickbacks in light of a recent decision from the U.S. Tenth Circuit Court of Appeals.
  • It is important for those who provide goods and services that are reimbursed by federal healthcare programs (including manufacturers and distributors of medical devices, surgical implants, pharmaceuticals, DME and related supplies and services) to evaluate the structure of their upstream and downstream relationships in order to both maximize the benefit of those relationships while simultaneously minimizing potentially significant False Claims Act exposure.  

Whistleblower activity has exploded at both the state and federal levels, so it is more important than ever for companies to take careful measures to avoid business practices that could trigger potential False Claims Act liability. Amendments to the False Claims Act (FCA), in combination with amendments to the Medicare/Medicaid anti-kickback statute (AKS) and widespread promotion of whistleblower cases by the plaintiffs' bar have made what was once a remote risk now a compliance imperative. Every current or former employee, every vendor, every customer and every outside contractor is a potential "bounty hunter" who has little to lose by filing a complaint – even if the allegations turn out to be wrong.

No industry has experienced more FCA enforcement than the healthcare industry and suppliers of medical goods and services. As an industry in which certain business practices that are normally considered legal and sound in other sectors of the economy are rendered illegal upon the introduction of reimbursements made directly or indirectly, in whole or in part, by federal healthcare programs, careful review of current procedures is imperative. One business practice in widespread use – compensating independent sales representatives using percentage-based commissions – has recently been the subject of a federal court of appeals opinion that left undisturbed a District Court's summary judgment decision finding such an arrangement to be unlawful as an illegal kickback. Although the case was not decided in the context of the FCA, its implications and application to FCA liability is clear.

Lessons Learned from the Joint Technology Decision

In the recent decision of Joint Technology, Inc. v. Weaver, 2014 WL 2199373 (10th Cir. May 28, 2014), the U.S. Court of Appeals for the Tenth Circuit affirmed the decision of a District Court that had invalidated a contract based on its finding that a percentage-based compensation arrangement between a distributor of durable medical equipment (DME) and its independent outside contractor sales agent was a violation of the AKS. According to the facts of the case, Joint Technology, Inc. entered into a contract in 2008 with an independent sales agent ("Weaver"), under which Weaver's compensation was calculated as a percentage of the sales of DME he generated for Joint Technology. Weaver terminated the contract approximately three years later, and Joint Technology subsequently filed suit alleging that Weaver had breached the contract. As a defense, Weaver asserted that the contract's commission-based compensation was a violation of the AKS, thereby rendering the contract illegal and unenforceable under the law applicable to the case. Joint Technology argued that the compensation arrangement fell within a safe harbor of the AKS and was not illegal – but the District Court disagreed with Joint Technology and granted summary judgment in favor of Weaver on the grounds that a rational jury would conclude that the contract violated the AKS and was therefore unenforceable under Oklahoma law. On appeal to the Tenth Circuit, the court "review[ed] the district court's rulings on summary judgment and ... affirm[ed] the judgment of the district court in [the] appeal." Id.

While Joint Technology is not the first civil case between private parties to find a commission-based compensation arrangement illegal under the AKS, what sets this case apart is the fact that the decision was affirmed by a federal court of appeals and therefore carries significant weight and has high visibility in the present whistleblower climate. In addition, unlike earlier cases, this decision has been handed down after the Patient Protection and Affordable Care Act amended the AKS to:

  • clarify that an AKS violation can occur without a person having either actual knowledge of the AKS or specific intent to violate it (thereby resolving a prior split among courts as to the statute's "knowingly and willfully" element)
  • make any claim that includes items or services resulting from a violation of the AKS a false or fraudulent claim for purposes of the FCA

This case therefore brings the potentially problematic nature of commission-based compensation arrangements for medical supplies and services into sharp focus. Given the widespread use of these types of commission-based arrangements and the huge number of annual transactions involved, these arrangements become attractive targets for whistleblowers and their attorneys who can potentially reap extensive financial rewards for their reporting.

FCA Consequences Are Wide Reaching and Potentially Devastating

In addition to the potentially detrimental, or even ruinous, financial consequences that can arise under the FCA, other potential issues that could arise under a compensation arrangement deemed to be illegal include:

  • exclusion from federal healthcare programs
  • government election to intervene in a qui tam action
  • government election to bring criminal prosecution
  • deferred prosecution and corporate integrity agreements
  • fines, civil penalties and treble damages
  • lack of contract enforceability
  • due diligence concerns in M&A, financing, and private equity placements
  • self-reporting considerations
  • public company disclosure obligations
  • investor derivative actions and business judgment rule inapplicability

Given the long-standing and widespread use of percentage-based commissions to compensate independent contractors in the medical goods and services supply chain, the industry would be well-served to renew past, but previously unsuccessful, efforts to lobby for a practical and workable safe harbor to cover these types of arrangements. Pending such an outcome, however, companies and individuals alike must be wary of the current and ever-changing legal environment in which they operate. Along these lines, and in light of the issues highlighted by the Joint Technology case, companies and individuals at all levels in the healthcare goods and services supply chain – from manufacturers to independent distributors – should evaluate their existing distribution, consignment and/or sales agency agreements to ascertain their legal compliance and level of risk and, where necessary, make adjustments to those relationships to maximize their value while simultaneously minimizing potentially significant FCA exposure.

Diverse Industries Are Impacted by Whistleblower Allegations

Regardless of the industry, whistleblower allegations can be extremely costly to defend while also wreaking havoc on a company's reputation. Holland & Knight's Healthcare and Life Sciences Team assists the full range of industry participants – including pharmaceutical, medical device, biotechnology, clinical laboratory and tissue banking companies, as well as private equity firms that invest in these types of companies – in all aspects of their operations. Our experienced team includes attorneys from across the firm who concentrate on the areas of law impacting healthcare entities, including compliance, litigation and dispute resolution, healthcare reform, regulatory law, legislative action, labor and employment, corporate, tax and general transactional issues, among others. Additionally, lawyers in the firm counsel companies and individuals in numerous other industries on FCA and other issues, including compliance, insurance, white collar defense and employment.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions